Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

BACKGROUND: Denosumab has been approved for the treatment of bone metastases from solid tumors. QL1206 is the first denosumab biosimilar and needs to be compared with denosumab in a phase III trial. OBJECTIVE: This phase III trial aims to compare the efficacy, safety, and pharmacokinetics between QL...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huiping, Huang, Yan, Chen, Zhendong, Zeng, Aiping, Zhang, Helong, Yu, Yan, Wei, Shihong, Li, Qingshan, Wang, Xiaojia, Wang, Xiangcai, Wang, Xiuwen, Yang, Runxiang, Dai, Xiumei, Bi, Minghong, Sun, Tao, Zhang, Qingyuan, Han, Cuicui, Li, Yujie, Kang, Xiaoyan, Liu, Yaxin, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971153/
https://www.ncbi.nlm.nih.gov/pubmed/36802320
http://dx.doi.org/10.1007/s40259-023-00579-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971153/
https://www.ncbi.nlm.nih.gov/pubmed/36802320
http://dx.doi.org/10.1007/s40259-023-00579-5

Ejemplares similares